Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 11/20 | 0.41 |
| ▸ | CA1 | P00915 | 10/20 | 0.41 |
| ▸ | CA9 | Q16790 | 8/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA3 | P07451 | 2/20 | 0.32 |
| ▸ | CA4 | P22748 | 2/20 | 0.32 |
| ▸ | CA6 | P23280 | 2/20 | 0.32 |
| ▸ | CA5A | P35218 | 2/20 | 0.32 |
| ▸ | CA7 | P43166 | 2/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL575713 | 0.87 | CA2 (0.44) | CA2CA1CA9KDM4EUSP2 | |
| SCHEMBL576009 | 0.87 | CA2 (0.44) | CA2CA1CA9KDM4EUSP2 | |
| SCHEMBL14779178 | 0.85 | CA2 (0.46) | CA2CA1CA9KDM4EUSP2 | |
| SCHEMBL2735589 | 0.85 | CA2 (0.46) | CA2CA1CA9KDM4EUSP2 | |
| SCHEMBL8398329 | 0.85 | CA2 (0.46) | CA2CA1CA9KDM4EUSP2 | |
| SCHEMBL23291930 | 0.85 | CA2 (0.46) | CA2CA1CA9KDM4EUSP2 | |
| SCHEMBL4952312 | 0.85 | CA2 (0.46) | CA2CA1CA9KDM4EUSP2 | |
| SCHEMBL116723 | 0.85 | CA2 (0.43) | CA2CA1CA9CA7 | |
| SCHEMBL18912060 | 0.84 | CA2 (0.43) | CA2CA1CA9KDM4EUSP2 | |
| SCHEMBL1032931 | 0.82 | CA2 (0.47) | CA2CA1CA9CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4447954-A1 | HETEROCYCLIC COMPOUNDS AS 5HT2A BIASED AGONISTS | Icahn School of Medicine at Mount Sinai (US) | 2024-10-23 | — | — | EP | disclosed |
| WO-2023114472-A1 | HETEROCYCLIC COMPOUNDS AS 5HT2A BIASED AGONISTS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-06-22 | — | — | WO | disclosed |
| US-20230013823-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2023-01-19 | — | — | US | disclosed |
| US-20220389007-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2022-12-08 | — | — | US | disclosed |
| EP-4038061-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | ViiV Healthcare UK (No.5) Limited (GB) | 2022-08-10 | — | — | EP | disclosed |
| EP-4038068-A1 | N-SUBSTITUTED-4-OXO-3,4-DIHYDROPYRIDO[2,3-D]PYRIMIDIN-2-YL DERIVATIVES AS INHIBITORS OF THE HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2022-08-10 | — | — | EP | disclosed |
| WO-2021064677-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2021-04-08 | — | — | WO | disclosed |
| WO-2021064571-A1 | N-SUBSTITUTED-4-OXO-3,4-DIHYDROPYRIDO[2,3-D]PYRIMIDIN-2-YL DERIVATIVES AS INHIBITORS OF THE HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2021-04-08 | — | — | WO | disclosed |
| CN-110214140-A | Estrogenic agents | 阿斯利康(瑞典)有限公司 | 2019-09-06 | — | — | CN | disclosed |
| CN-106478651-B | Substituted heteroaryl compound and combinations thereof and purposes | 广东东阳光药业有限公司 | 2019-07-09 | — | — | CN | disclosed |
| WO-2014047397-A1 | FLUOROALKYL AND FLUOROCYCLOALKYL 1,4-BENZODIAZEPINONE COMPOUNDS AS NOTCH|INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-03-27 | — | — | WO | disclosed |
| WO-2014047397-A1 | FLUOROALKYL AND FLUOROCYCLOALKYL 1,4-BENZODIAZEPINONE COMPOUNDS AS NOTCH|INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-03-27 | — | — | WO | disclosed |
| CN-102985424-A | 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of jak kinases | ARRAY BIOPHARMA INC | 2013-03-20 | — | — | CN | disclosed |
| CN-101312944-B | Organic sulfur compounds and their use as arthropodicides | SUMITOMO CO LTD | 2013-03-06 | — | — | CN | disclosed |
| EP-2513110-A1 | 1, 7 - DIAZACARBAZOLES AND THEIR USE IN THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2012-10-24 | — | — | EP | disclosed |
| CN-102333569-A | Amine or amino alcohols as glyt1 inhibitors | HOFFMANN LA ROCHE | 2012-01-25 | — | — | CN | disclosed |
| US-20110183938-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2011-07-28 | — | — | US | disclosed |
| WO-2011073263-A1 | 1, 7 - DIAZACARBAZOLES AND THEIR USE IN THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-23 | — | — | WO | disclosed |
| EP-1480739-A2 | APPARATUS FOR SYNTHESIS OF RADIOLABELED COMPOUNDS | Bioscan, Inc. (US) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003064678-A2 | APPARATUS FOR SYNTHESIS OF RADIOLABELED COMPOUNDS | BIOSCAN, INC. (US) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389007-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, POLR2E, POLR2H | CA2 4429/4885CA1 4716/4885CA9 4436/4885 |
| US-20230013823-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, POLR2E, POLR2H | CA2 4429/4885CA1 4716/4885CA9 4436/4885 |
| US-20110183938-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | CHEK1, CHEK2, BUB1B | CA2 1764/4885CA1 3208/4885CA9 1154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.